ABB: Our Way forward
10.6.2020 15:00:00 EEST | Business Wire | Press release
ABB will be hosting an investor webcast at 14:00 CEST today, June 10, at which CEO, Björn Rosengren, will be giving his initial impressions on the Group’s strategy since he joined the company at the beginning of the year, as well as details on his immediate priorities. Highlights will include:
– ABB-OS evolves into new operating model ABB Way
– Clear focus on decentralized business model and 18 fully accountable divisions
– Prioritization of stability and profitability before growth
– Active portfolio management to play key role
– Combination of COVID-19 and oil price drop will lead to challenges over the coming quarters
– Group mid-term financial targets remain in place
– Divestment of Power Grids on track to be completed end Q2, 2020
– ABB on track to deliver $500 million ABB-OS cost savings
“After my first 100 days as CEO, I can truly say: ABB has a good foundation to build on. Our technology and products are well aligned to key market trends and customer needs such as the electrification of transport, automated manufacturing, digital solutions and increased sustainable productivity,” said Björn Rosengren. “We will now leverage this strong position to create superior value for our customers, employees and shareholders. We will do this by evolving our decentralized business model, strengthening our performance management culture, putting stability and profitability before growth, and driving active portfolio management.”
The company’s mid-term financial targets of a 3-6 percent comparable revenue growth per year, an operational EBITA margin of 13-16 percent, ~100 percent cash conversion rate, 15-20 percent ROCE and EPS growing at a faster rate than revenue growth, remain in place. An update on the strategy, including long-term 2030 sustainability targets, will be provided later this year at the Group’s Capital Market Day in November 2020.
Currently, ABB is still facing challenging quarters ahead due to the COVID-19 global pandemic and a drop in the oil price. This has led to a decline in demand, for example, in the automotive and power generation end markets, while travel restrictions and supply chain constraints also have an impact on business. Nevertheless, the Chinese market continues to recover, while the transport, food & beverage and data center sectors remain relatively resilient.
“The health and safety of all our stakeholders remains the key priority in these difficult times, while we are also intensifying our efforts to mitigate the crisis by increasing our number of virtual customer visits, adjusting production capacity to demand and managing cash tightly,” said Rosengren.
At today’s event, CFO Timo Ihamuotila will comment on ABB’s capital allocation priorities, which remain unchanged. The sale of the Power Grids business to Hitachi is expected to be completed at the end of the second quarter of 2020 and ABB remains committed to a share buyback program using net cash proceeds from the transaction. ABB is planning to execute this in an efficient and responsible way, taking account of the prevailing circumstances. Cash will also be returned to shareholders in the form of rising sustainable dividends per share and ABB aims to retain a “single A” credit rating.
Creating superior value through new operating model ABB Way
A key element of ABB’s strategy to create superior value is the ongoing decentralization of the business model. ABB has successfully discontinued its longstanding matrix organization over the last 18 months, with more responsibility shifted to the four business areas of Electrification, Industrial Automation, Motion and Robotics & Discrete Automation.
Going forward, a new operating model called ABB Way will provide a governance framework of processes and policies, connecting the business areas and divisions to the corporate center and uniting the Group under the ABB brand. ABB Way is evolving from the current ABB-OS, which is on track to deliver the targeted $500 million cost savings, with the full run-rate benefit during 2021.
After having been successfully launched in 2016, the ABB Ability™ digital platform will also be managed by the business areas and no longer in the corporate center. This will enable them to create software solutions more efficiently and quickly. ABB Ability™ has more than 160 digital solutions, boasting top-tier software partnerships with Microsoft, Hewlett Packard Enterprises and Ericsson, for example.
In a further step of moving operating activities even closer to the customer, ABB will empower 18 divisions comprised within the four business areas. More details on the divisions, as well as updated strategies for the business areas, will be provided at the Capital Markets Day in November 2020. ABB will continue to report its financial results based on the four business areas.
“We will strengthen our performance management through a new scorecard system based on a very transparent and standardized set of KPIs. Here, I expect our management to focus on having a stable structure and profitability before embarking on growth,” said Rosengren. “The benchmark is for each of the divisions to be number one or two in its respective market segment.”
As part of this new divisional focus, ABB will also further strengthen its ongoing portfolio review process to ascertain whether ultimately ABB is the best owner in terms of strategic attractiveness, value creation potential and structural fit.
“Portfolio management will play an even more important role going forward and we will not shy away from fixing, exiting or growing divisions,” said Rosengren. “At the same time, no major acquisitions are planned by ABB in the mid-term.”
As part of the ABB Way, corporate functions will focus on financial, strategic and governance activities in the future and have a reduced headcount of less than 1,000 employees worldwide. At the beginning of 2019, roughly 18,000 employees were still in corporate functions, the majority of whom were then gradually transferred into the business areas.
ABB (ABBN: SIX Swiss Ex) is a leading global engineering company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by 144,000 talented employees in over 100 countries. www.abb.com
Important notice about forward-looking information
This press release includes forward-looking information and statements which are based on current expectations, estimates and projections about the factors that may affect our future performance, including the economic conditions of the regions and industries that are major markets for ABB. These expectations, estimates and projections are generally identifiable by statements containing words such as “anticipates”, “expects,” “believes,” “estimates,” “plans”, “targets”, “on track” or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release and which could affect our ability to achieve any or all of our stated targets. The important factors that could cause such differences include, among others, business risks associated with the volatile global economic environment and political conditions, costs associated with compliance activities, market acceptance of new products and services, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005398/en/
Contact information
For more information please contact:
Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com
Investor Relations
Phone: +41 43 317 71 11
Email: investor.relations@ch.abb.com
ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
